References
- Centers for Disease Control and Prevention NCfHS. Multiple Cause of Death 1999-2016 on CDC WONDER Online Database. Data are from the Multiple Cause of Death Files, 1999–2016, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program 2017. [cited 2018 Apr 13]. Available from: https://wonder.cdc.gov/controller/saved/D77/D38F188
- Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH series H-52). Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017.
- Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med. 2009 Jul;10(Suppl 2):S124–S133.
- Cicero TJ, Ellis MS, Kasper ZA. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers. Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):56–62.
- Iwanicki JL, Severtson SG, McDaniel H, et al. Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States. PLoS One. 2016;11(12):e0167499.
- Cassidy TA, Oyedele N, Mickle TC, et al. Patterns of abuse and routes of administration for immediate-release hydrocodone combination products. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1071–1082.
- Kumar K, Gulotta LV, Dines JS, et al. Unused opioid pills after outpatient shoulder surgeries given current perioperative prescribing habits. Am J Sports Med. 2017 Mar;45(3):636–641.
- Maughan BC, Hersh EV, Shofer FS, et al. Unused opioid analgesics and drug disposal following outpatient dental surgery: a randomized controlled trial. Drug Alcohol Depend. 2016 Nov 1;168:328–334.
- Bicket MC, Long JJ, Pronovost PJ, et al. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg. 2017 Nov 1;152(11):1066–1071.
- Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011 Jul;37(4):205–217.
- Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004;23(4):1–9.
- Lankenau SE, Teti M, Silva K, et al. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012 Jan;23(1):37–44.
- Moorman-Li R, Motycka CA, Inge LD, et al. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T. 2012 Jul;37(7):412–418.
- Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J. 2009 May 29;6:8.
- Centers for Disease Control and Prevention. HIV Surveillance Report 2015 [cited 2018 Feb 9]. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
- Lankenau SE, Kecojevic A, Silva K. Associations between prescription opioid injection and Hepatitis C virus among young injection drug users. Drugs (Abingdon Engl). 2015;22(1):35–42.
- Greene D. Total necrosis of the intranasal structures and soft palate as a result of nasal inhalation of crushed OxyContin. Ear Nose Throat J. 2005 Aug;84(8):512,514, 516.
- Yewell J, Haydon R, Archer S, et al. Complications of intranasal prescription narcotic abuse. Ann Otol Rhinol Laryngol. 2002 Feb;111(2):174–177.
- Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011 Oct 19;8:29.
- Cicero TJ, Ellis MS, Surratt HL, et al. Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States. Pain. 2013 Dec;154(12):2639–2648.
- Cicero TJ, Ellis MS. The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse. Dialogues Clin Neurosci. 2017 Sep;19(3):259–269.
- Califf RM, Woodcock J, Ostroff S, et al. A proactive response to prescription opioid abuse. N Engl J Med. 2016 Apr 14;374(15):1480–1485.
- Gottlieb S FDA takes important steps to stem the tide of opioid misuse and abuse 2017 [cited 2018 Feb 9]. Available from: https://blogs.fda.gov/fdavoice/index.php/2017/09/fda-takes-important-steps-to-stem-the-tide-of-opioid-misuse-and-abuse/
- National Conference of State Legislatures. Prescribing policies: states confront opioid overdose epidemic 2017. [cited 2018 Feb 9]. Available from: http://www.ncsl.org/Portals/1/Documents/Health/prescribingOpioids_final01-web.pdf
- American Pharmacists Association. Washington adopts statewide drug take-back legislation 2018. [cited 2018 Apr 16]. Available from: https://www.pharmacist.com/article/washington-adopts-statewide-drug-take-back-legislation
- Anson P. Health insurer to adopt 5 day limit on opioids 2017. [cited 2018 Feb 9]. Available from: https://www.painnewsnetwork.org/stories/2017/6/27/insurer-to-adopt-5-day-limit-on-opioids
- Blue Cross Blue Shield of North Carolina. Blue Cross NC announces new opioid prescription and treatment policies 2018. [cited 2018 Apr 16]. Available from: http://mediacenter.bcbsnc.com/news/blue-cross-nc-announces-new-opioid-prescription-and-treatment-policies
- Cigna Corporation. Cigna is committed to reducing opioid use: removing OxyContin from group commercial drug lists on 1/ 1/18 2017 [cited 2018 Feb 9]. Available from: https://www.cigna.com/newsroom/news-releases/2017/cigna-is-committed-to-reducing-opioid-use-removing-oxycontin-from-group-commercial-drug-lists-on-1118
- Gudin J, Levy-Cooperman N, Kopecky EA, et al. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015 Nov;16(11):2142–2151.
- CVS Health. CVS health responds to nation’s opioid crisis 2017. [cited 2018 Feb 9]. Available from: https://cvshealth.com/thought-leadership/cvs-health-enterprise-response-opioid-epidemic/cvs-health-responds-to-nations-opioid-crisis
- CVS. CVS Caremark opioid quantity limits pharmacy reference guide 2018. [cited 2018 Apr 16]. Available from: https://www.caremark.com/portal/asset/Opioid_Reference_Guide.pdf
- Drug Enforcement Administration. DEA reduces amount of opioid controlled substances to be manufactured in 2017 2016. [cited 2018 Jun 20]. Available from: https://www.dea.gov/divisions/hq/2016/hq100416.shtml
- Drug Enforcement Administration. DEA proposes reduction to amount of controlled substances to be manufactured in 2018 2017. [cited 2018 Jun 20]. Available from: https://www.dea.gov/divisions/hq/2017/hq080417.shtml
- Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ. 2017 Oct 19;359:j4792.
- Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Curr Opin Anaesthesiol. 2009 Oct;22(5):588–593.
- Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014 Jun;28(6):491–496.
- Schjerning O, Rosenzweig M, Pottegard A, et al. Abuse potential of pregabalin: a systematic review. CNS Drugs. 2016 Jan;30(1):9–25.
- Houze B, El-Khatib H, Arbour C. Efficacy, tolerability, and safety of non-pharmacological therapies for chronic pain: an umbrella review on various CAM approaches. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):192–205.
- Kroll HR. Exercise therapy for chronic pain. Phys Med Rehabil Clin N Am. 2015 May;26(2):263–281.
- Carvalho E, Bettger JP, Goode AP. Insurance coverage, costs, and barriers to care for outpatient musculoskeletal therapy and rehabilitation services. N C Med J. 2017 Sep-Oct;78(5):312–314.
- Katz C, El-Gabalawy R, Keyes KM, et al. Risk factors for incident nonmedical prescription opioid use and abuse and dependence: results from a longitudinal nationally representative sample. Drug Alcohol Depend. 2013 Sep 1;132(1–2):107–113.
- Kaye AD, Jones MR, Kaye AM, et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse (Part 2). Pain Physician. 2017 Feb;20(2S):S111–S133.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. JAMA. 2016 Apr 19;315(15):1624–1645.
- Centers for Disease Control and Prevention. CDC vital signs: opioid prescribing 2017. [cited 2018 Feb 9]. Available from: https://www.cdc.gov/vitalsigns/pdf/2017-07-vitalsigns.pdf
- Centers for Disease Control and Prevention. Prescription drug monitoring programs (PDMPs) 2017. [cited 2018 Feb 9]. Available from: https://www.cdc.gov/drugoverdose/pdf/pdmp_factsheet-a.pdf
- Drug Enforcement Administration. Drug Enforcement Administration collects record number of unused pills as part of its 14th Prescription Drug Take Back day 2017. [cited 2018 Feb 9]. Available from: https://www.justice.gov/usao-ndal/pr/drug-enforcement-administration-collects-record-number-unused-pills-part-its-14th
- Pergolizzi JV Jr., Raffa RB, Taylor R Jr., et al. Abuse-deterrent opioids: an update on current approaches and considerations. Curr Med Res Opin. 2018 Jan 10;34:711–723.
- Center for Drug Evaluation and Research. Abuse-deterrent opioids – evaluation and labeling 2015. [cited 2018 Feb 9]. Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdf
- Coplan PM, Chilcoat HD, Butler SF, et al. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016 Sep;100(3):275–286.
- Severtson SG, Ellis MS, Kurtz SP, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016 Nov 1;168:219–229.
- US Food and Drug Administration. Drugs@FDA: FDA approved drug products 2018. [cited 2018 Apr 17]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209777
- RoxyBond™ (oxycodone hydrochloride) tablets [package insert]. Morristown (NJ): Inspirion Delivery Sciences, LLC; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209777lbl.pdf.
- Webster LR, Iverson M, Pantaleon C, et al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal human abuse potential study of oxycodone ARIR, a novel, immediate-release, abuse-deterrent formulation. Pain Med. 2018 Mar 28. doi: 10.1093/pm/pny043. [Epub ahead of print]
- Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016 Jul 28;375(4):357–368.